ClinicalTrials.gg
Status unknownNCT05369767Updated Nov 30, 2022

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects

A Phase 1 interventional study of SAD, SHR-2004 and SAD, SHR-2004 placebo in Prevention of Arterial and Venous Thrombosis, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.

Enrollment
35th of 41
64 · median 360
Started
2022
with 10 others
Phase 1
Only one
of the 59
Registered
40th of 59
by date
Lead sponsor
2 of 59
Beijing Suncadia Pharmaceuticals Co., Ltd

Among the 59 studies in Venous Thrombosis with a site in China, this one is the 35th largest by enrollment of the 41 interventional ones that give a count, is one of 11 that started in 2022, is the only one in phase 1, and was the 40th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Venous Thrombosis with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of SHR-2004 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-2004 injection in healthy subjects.

03

Conditions studied

  • Prevention of Arterial and Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. males or females, aged 18-55;
  2. (BMI) between 19 kg/m2 to 28 kg/m2, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg.

Exclusion criteria

Exclusion Criteria:

  1. previous medical history of coagulation or bleeding disorders;
  2. known risks of bleeding or thrombosis, such as recurrent gingival bleeding, spontaneous bleeding, haemorrhoids, gastrointestinal ulcers, or other high-risk bleeding diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    SAD, SHR-2004

    Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 injection

    Drug: SAD, SHR-2004

  • Placebo comparator
    SAD, SHR-2004 placebo

    Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 placebo injection

    Drug: SAD, SHR-2004 placebo

Interventions

  • DrugSAD, SHR-2004

    Ascending dose

  • DrugSAD, SHR-2004 placebo

    Ascending dose

06

What researchers measure

Primary outcomes

  1. To assess the number of subjects with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: up to day 113

07

Study locations

1 site
  • Affiliated Drum Tower Hospital of Nanjing University Medical school
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Jan 2023, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 11, 2022
StartActual
May 24, 2022
Primary completionEst.
Jan 30, 2023
CompletionEst.
Jan 30, 2023
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05369767
Responsible party
Sponsor
First posted
May 11, 2022
Start date
May 24, 2022
Primary completion
Jan 30, 2023 (estimated)
Completion
Jan 30, 2023 (estimated)
Last update
Nov 30, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion